Physician profile
Alfredo Ramirez
NPI 1043851033
$7,757.09
in general payments reported to CMS, 2019-2025
18 companies · $863 in 2025
The $863 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $1,810 · 2023: $2,979 · 2024: $1,257 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,850.78 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,149.39 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $782.45 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $718.96 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $606.14 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Lundbeck LLC | $513.99 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $478.54 | 2022-2025 | Auvelity |
| Abbvie INC. | $372.86 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $300.19 | 2023-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $243.05 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $173.54 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.82 | 2022-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $103.69 | 2022-2023 | Jornay Pm |
| Acadia Pharmaceuticals INC | $81.39 | 2022-2024 | Nuplazid |
| Tris Pharma INC | $69.56 | 2023-2024 | Dyanavel Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $67.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.32 | 2021 | |
| Vanda Pharmaceuticals INC. | $25.68 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.